Amylyx shareholders elect two Class II directors and ratify Deloitte as auditor

Amylyx Pharmaceuticals, Inc.

George Mclean Milne Jr. and Paul Fonteyne elected as Class II directors; term until 2026.
Milne received 44,362,315 votes for, 9,410,140 withheld; Fonteyne 44,736,816 for, 9,035,639 withheld.
Ratification of Deloitte & Touche as independent auditor for FY 2023 passed with 57,585,098 votes for.
No other matters were submitted to or voted on at the annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amylyx Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Amylyx Pharmaceuticals, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

The stockholders of the Company elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2026 or until their successors have been duly elected and qualified or until their earlier resignation or removal.

View on SEC.gov

Browse all shareholder votes →

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-164027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.